- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.12.25 | MICROBA LIFE SCIENCES LIMITED: Microba receives $3 million R&D Tax Incentive Refund | - | ASX | ||
| 21.11.25 | MICROBA LIFE SCIENCES LIMITED: Release of Restricted Securities | - | ASX | ||
| 20.11.25 | MICROBA LIFE SCIENCES LIMITED: Initial Director's Interest Notice - Stephane Chatonsky | - | ASX | ||
| 20.11.25 | MICROBA LIFE SCIENCES LIMITED: Final Director's Interest Notice - Richard Bund | - | ASX | ||
| MICROBA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.11.25 | MICROBA LIFE SCIENCES LIMITED: Final Director's Interest Notice - Hyungtae Kim | - | ASX | ||
| 19.11.25 | MICROBA LIFE SCIENCES LIMITED: Results of Annual General Meeting | - | ASX | ||
| 12.11.25 | MICROBA LIFE SCIENCES LIMITED: Change in substantial holding | - | ASX | ||
| 11.11.25 | MICROBA LIFE SCIENCES LIMITED: Board Renewal | - | ASX | ||
| 31.10.25 | MICROBA LIFE SCIENCES LIMITED: Becoming a substantial holder | - | ASX | ||
| 28.10.25 | Microba Q1 FY26 slides: 145% core test growth amid strategic transition | 1 | Investing.com | ||
| 27.10.25 | MICROBA LIFE SCIENCES LIMITED: Q1 FY26 Quarterly Investor Presentation & Webinar | - | ASX | ||
| 27.10.25 | MICROBA LIFE SCIENCES LIMITED: Q1 FY26 Quarterly Activities Report & Appendix 4C | - | ASX | ||
| 23.10.25 | MICROBA LIFE SCIENCES LIMITED: Details of Q1 FY26 Quarterly Report, Appendix 4C & Webinar | - | ASX | ||
| 17.10.25 | MICROBA LIFE SCIENCES LIMITED: Annual Report to Shareholders | - | ASX | ||
| 17.10.25 | MICROBA LIFE SCIENCES LIMITED: Letter to Shareholders, Notice of AGM & Proxy Form | 1 | ASX | ||
| 30.09.25 | MICROBA LIFE SCIENCES LIMITED: Date of AGM and Closing Date for Director Nominations | - | ASX | ||
| 19.09.25 | MICROBA LIFE SCIENCES LIMITED: Change of Director's Interest Notice - G Tyson & H Kim | - | ASX | ||
| 18.09.25 | MICROBA LIFE SCIENCES LIMITED: Change of Director's Interest Notice - Richard Bund | 3 | ASX | ||
| 16.09.25 | MICROBA LIFE SCIENCES LIMITED: Change of Director's Interest Notice - Richard Bund | - | ASX | ||
| 01.09.25 | MICROBA LIFE SCIENCES LIMITED: Change in substantial holding | - | ASX |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VENTYX BIOSCIENCES | 13,815 | +0,62 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| QIAGEN | 41,290 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 23,590 | +52,49 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 14,230 | +25,93 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 42,830 | -19,01 % | Regencell Bioscience is the top performing pharma stock YTD | ||
| ALUMIS | 18,040 | +0,67 % | What's Going On With Alumis Stock Thursday? | ||
| PRAXIS PRECISION MEDICINES | 292,08 | -0,15 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| PHATHOM PHARMACEUTICALS | 15,460 | -14,49 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| IMMUNEERING | 4,650 | -44,18 % | Immuneering Corporation: Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP | - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently... ► Artikel lesen | |
| EVOTEC | 6,338 | +0,76 % | EQS-News: Evotec SE: Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec ernennt Dr. Sarah Fakih als EVP, Leiterin Global Communications und Investor Relations
01.01.2026 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 24,870 | +6,83 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,31 | -0,08 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ERASCA | 5,210 | +0,77 % | Erasca stock pulls back after 25% jump, Stifel cites competitor data | ||
| RECURSION PHARMACEUTICALS | 4,730 | -2,67 % | Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates | ||
| BIONTECH | 84,60 | -1,34 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen |
MICROBA LIFE SCIENCES LIMITED gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,038 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MICROBA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.